Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumors including the following * Recurrent high-grade glioma * Recurrent metastatic brain tumors * Recurrent primary brain tumor including primary CNS lymphoma * Other refractory solid tumors * Unresectable disease for which standard curative or palliative measures do not exist or are no longer effective * Measurable or nonmeasurable disease PATIENT CHARACTERISTICS: Inclusion criteria: * Karnofsky performance status 60-100% * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Serum creatinine ≤ 1.5 x upper limit of normal (ULN) * Total bilirubin ≤ 2.0 mg/dL * AST ≤ 4.0 x ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Patient must be able to understand and is willing to sign a written informed consent document Exclusion criteria: * Any of the following conditions: * Myocardial infarction within the past 6 months or New York Heart Association class III or IV heart failure * Uncontrolled angina * Severe uncontrolled ventricular arrhythmias * ECG evidence of acute ischemia or active conduction system abnormalities * Any ECG abnormalities prior to study entry must be documented by the investigator as not medically relevant * Serious medical or psychiatric illness that would, in the opinion of the investigator, potentially interfere with the completion of treatment * History of sensitivity to boron or mannitol PRIOR CONCURRENT THERAPY: Inclusion criteria: * At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea-containing chemotherapy), immunotherapy, or radiotherapy and recovered * More than 10 days since prior anticonvulsant drugs that induce hepatic metabolic enzymes for patients in group A * Recovered from major surgery * Corticosteroids for cerebral edema allowed provided the patient is on a stable dose for at least 1 week Exclusion criteria: * Patients enrolled on another clinical trial * HIV-positive patients on antiretroviral therapy * Concurrent chemotherapy or radiotherapy * Patient requires anti-seizure medication but is not on a stable dose and agent of anti-seizure medication